Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04395859

Acronym

COVIDIV

Enrollment

233

Registered

2020-05-20

Start date

2020-05-27

Completion date

2022-02-15

Last updated

2022-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Keywords

Intravitreal Injections, Anti-angiogenics, COVID19

Brief summary

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

Interventions

PROCEDUREQuestionnaire

At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment

OTHERData collection up to 1 year

Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative AMD, diabetic macular edema or secondary to retinal venous occlusion ...) * Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of French confinement)

Exclusion criteria

* Refusal to participate

Design outcomes

Primary

Measure	Time frame	Description
Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic	Baseline (Before confinement) and 6 months after resumption of follow-up	Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026